ADC Therapeutics (ADCT) Assets (2019 - 2026)
ADC Therapeutics (ADCT) posted Assets of $291.5 million for Q1 2026, down 9.8% sequentially from $323.2 million in Q4 2025, and up 6.96% YoY from $272.5 million in Q1 2025.
ADC Therapeutics (ADCT) Assets (2019 - 2026) Analysis & Trends
ADC Therapeutics has reported Assets for 8 years, with the latest figure at $291.5 million in Q1 2026.
- Quarterly Assets rose 6.96% year-over-year to $291.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $291.5 million (up 6.96% YoY) and the FY2025 annual result came in at $323.2 million, changed 0.36% from the prior year.
- Assets retreated to $291.5 million in Q1 2026 per ADCT's latest filing, from $323.2 million in the prior quarter.
- Over five years, Assets peaked at $581.9 million in Q1 2022 and troughed at $272.5 million in Q1 2025.
- A 5-year average of $398.3 million and a median of $354.8 million in 2023 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2024: Assets rose 26.03% in 2022, then sank 34.15% in 2024.
- Over 5 years, Assets stood at $490.9 million in 2022, then dropped by 27.72% to $354.8 million in 2023, then slipped by 9.25% to $322.0 million in 2024, then rose by 0.36% to $323.2 million in 2025, then fell by 9.8% to $291.5 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $291.5 million, $323.2 million, and $289.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 19.82 Bn |
| 10 | ADC Therapeutics | 151.61 Mn | -67.50 Mn | 17.14 Mn | 279.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 279.38 Mn |
| Mar 31, 2026 | 291.50 Mn |
| Dec 31, 2025 | 323.15 Mn |
| Sep 30, 2025 | 289.76 Mn |
| Jun 30, 2025 | 321.56 Mn |
| Mar 31, 2025 | 272.54 Mn |
| Dec 31, 2024 | 321.98 Mn |
| Sep 30, 2024 | 349.08 Mn |
| Jun 30, 2024 | 371.78 Mn |
| Mar 31, 2024 | 307.97 Mn |
| Dec 31, 2023 | 354.78 Mn |
| Sep 30, 2023 | 466.90 Mn |
| Jun 30, 2023 | 507.30 Mn |
| Mar 31, 2023 | 467.67 Mn |
| Dec 31, 2022 | 490.86 Mn |
| Sep 30, 2022 | 531.76 Mn |
| Jun 30, 2022 | 520.46 Mn |
| Mar 31, 2022 | 581.89 Mn |
| Dec 31, 2021 | 617.97 Mn |
| Sep 30, 2021 | 637.98 Mn |